KATHLEEN KILCOYNE: Open Payments
NPI 1639335862 · DENVILLE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,867 in 72 payments from 11 companies in 2025. Trend: 2023 $1,604 · 2024 $2,060 · 2025 $1,867
Food & beverage: $1,867
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 8 | $330 |
| Axsome Therapeutics, Inc. | 12 | $271 |
| E.R. Squibb & Sons, L.L.C. | 3 | $254 |
| Otsuka America Pharmaceutical, Inc. | 5 | $226 |
| ABBVIE INC. | 20 | $203 |
| Alkermes, Inc. | 6 | $165 |
| Supernus Pharmaceuticals, Inc. | 1 | $125 |
| Neurocrine BioSciences, Inc. | 6 | $111 |
| Lundbeck LLC | 5 | $92 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $73 |
Products named: COBENFY, REXULTI, Auvelity, VRAYLAR, AUSTEDO XR, UZEDY, Qelbree, INGREZZA.
Industry payments across NJ — which companies pay providers there.
